Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Download Data

Edgewise Therapeutics Inc Total Long-Term Assets 2 year CAGR for the year ending December 31, 2023: 71.28%

Edgewise Therapeutics Inc Total Long-Term Assets 2 year CAGR is 71.28% for the year ending December 31, 2023, a -67.42% change year over year. Total Long-Term Assets is the sum of property, plant, equipment, intangible assets, investments, and other long-term assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Edgewise Therapeutics Inc Total Long-Term Assets for the year ending December 31, 2022 was USD 15.15 M, a 241.00% change year over year.
Edgewise Therapeutics Inc Total Long-Term Assets for the year ending December 31, 2021 was USD 4.44 M, a 198.05% change year over year.
Edgewise Therapeutics Inc Total Long-Term Assets for the year ending December 31, 2020 was USD 1.49 M, a 199.40% change year over year.
Edgewise Therapeutics Inc Total Long-Term Assets for the year ending December 31, 2019 was USD 498.00 K.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends